Nexalin technology expresses strong support for health tech investment act to advance medicare reimbursement for ai-enabled devices

Houston, tx, april 21, 2025 (globe newswire) -- nexalin technology, inc. (nasdaq: nxl; nxliw) (the “company” or “nexalin”) the leader in deep intracranial frequency stimulation (difs™) of the brain, today announced its support for the health tech investment act (s. 1399) — bipartisan legislation introduced in the united states senate that would expand medicare reimbursement opportunities for fda-cleared or approved medical devices that incorporate artificial intelligence (ai) or machine learning.
NXL Ratings Summary
NXL Quant Ranking